SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Reminds Investors of Investigations of NAV, UROV, AKER, and EMIS Mergers
01. Dezember 2020 11:09 ET
|
Rigrodsky & Long, P.A.
WILMINGTON, Del., Dec. 01, 2020 (GLOBE NEWSWIRE) -- Rigrodsky & Long, P.A. announces that it is investigating: Navistar International Corporation (NYSE: NAV) regarding possible breaches of...
SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Reminds Investors of Investigations of HDS, UROV, AKER, and TGC Mergers
19. November 2020 18:11 ET
|
Rigrodsky & Long, P.A.
WILMINGTON, Del., Nov. 19, 2020 (GLOBE NEWSWIRE) -- Rigrodsky & Long, P.A. announces that it is investigating: HD Supply Holdings, Inc. (NASDAQ GS: HDS) regarding possible breaches of...
SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Announces Investigation of Akers Biosciences, Inc. Merger
13. November 2020 11:31 ET
|
Rigrodsky & Long, P.A.
WILMINGTON, Del., Nov. 13, 2020 (GLOBE NEWSWIRE) -- Rigrodsky & Long, P.A. announces that it is investigating Akers Biosciences, Inc. (“Akers”) (NASDAQ GS: AKER) regarding possible breaches of...
Akers Biosciences Announces $6.8 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules
11. August 2020 08:00 ET
|
Akers Biosciences Inc.
Thorofare, New Jersey, Aug. 11, 2020 (GLOBE NEWSWIRE) -- Akers Biosciences, Inc. (the “Company”) (NASDAQ: AKER), today announced that it has entered into definitive agreements with several...
Akers Biosciences Announces $4.8 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules
14. Mai 2020 13:00 ET
|
Akers Biosciences Inc.
Thorofare, New Jersey, May 14, 2020 (GLOBE NEWSWIRE) -- Akers Biosciences, Inc. (the “Company”) (NASDAQ: AKER), a developer of rapid health information technologies, today announced that it has...
Akers Biosciences and Premas Biotech Announce Successful Completion of Vaccine Prototype & Obtained First Images of VLP
14. Mai 2020 09:33 ET
|
Akers Biosciences Inc.
Thorofare, New Jersey, May 14, 2020 (GLOBE NEWSWIRE) -- Akers Biosciences, Inc. (the “Company”) (NASDAQ: AKER), a developer of rapid health information technologies, today announced that Premas...
Akers Biosciences Announces $4.6 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules
07. April 2020 10:53 ET
|
Akers Biosciences Inc.
Thorofare, New Jersey, April 07, 2020 (GLOBE NEWSWIRE) -- Akers Biosciences, Inc. (the “Company”) (NASDAQ: AKER), a developer of rapid health information technologies, today announced that it has...
Akers Biosciences Acquires Licenses to Coronavirus Vaccine Candidate from Premas Biotech
24. März 2020 09:00 ET
|
Akers Biosciences Inc.
Established D-Crypt™ platform will be used to develop a proof-of-concept targeting three of the top five viral vaccine protein candidates for CoronavirusCurrent Regulatory environment could lead to...
Akers Biosciences, Inc. Provides Notice of Proposed Settlement of Derivative Litigation
17. Januar 2020 17:00 ET
|
Akers Biosciences Inc.
Thorofare, New Jersey, Jan. 17, 2020 (GLOBE NEWSWIRE) -- Akers Biosciences, Inc. (the “Company”) (NASDAQ: AKER), a developer of rapid health information technologies, today announced that it reached...
Akers BioSciences, Inc. Announces Closing of Approximately $8 Million Public Offering
09. Dezember 2019 11:40 ET
|
Akers Biosciences Inc.
Thorofare, New Jersey, Dec. 09, 2019 (GLOBE NEWSWIRE) -- Akers Biosciences, Inc. (the “Company” or “we”) (NASDAQ: AKER), a developer of rapid health information technologies, today announced the...